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Abstract
Intracellular Gα subunits represent potential therapeutic targets for a number of diseases. Here we
describe three classes of new molecules that modulate G protein signaling by direct targeting of
Gα. Using mRNA display, we have identified unique peptide sequences that bind Gαi1. Functionally,
individual peptides were found that either enhance or repress basal levels of G protein-activated
inwardly rectifying potassium (GIRK) channel signaling—a downstream effector of G protein
activation—indicating that the peptides directly turn G proteins on or off in vivo. A third functional
class acts as a signaling attenuator—basal GIRK channel activity is unaffected but responses to
repeated G protein activation are reduced. These data demonstrate that G protein-directed ligands
can achieve similar physiological effects as those resulting from classical receptor targeting and may
serve as leads for developing new classes of therapeutics.
Heterotrimeric guanine nucleotide-binding proteins (G proteins), composed of α, β, and γ
subunits, play a critical role in communicating extracellular signals to intracellular signal
transduction pathways through membrane-spanning G protein-coupled receptors (GPCRs)
(1,2). Activation of GPCRs by extracellular agonists triggers the exchange of GDP with GTP
in the Gα subunit and dissociation of Gβγ heterodimers from Gα-GTP, which both regulate
multiple effectors. Gβγ subunits, for example, can directly regulate adenylyl cyclase,
phospholipase Cβ isozymes, and GIRK channels (3). GTP hydrolysis by the inherent Gα
guanosine triphosphatase (GTPase) activity, a reaction catalyzed by various GTPase-activating
proteins (GAPs), returns Gα to the GDP-bound state and results in reassociation with Gβγ and
termination of signaling.
Intracellular G proteins have potential as drug targets for a number of diseases (4–7). The large
number of possible combinations of α, β, and γ subunits suggest that direct G protein ligands
could affect individual effector pathways and/or modify signaling kinetics with great
specificity (5,8,9). The G protein regulatory (GPR) or GoLoco motif, for example, is a peptide
guanine nucleotide dissociation inhibitor (GDI) which is implicated in receptor-independent
signaling (10,11). Other recent advances include the identification of ligands for Gβγ that affect
downstream signaling pathways using peptide (12) or small molecule (13) libraries.
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A selection for peptides that bind to Gα subunits yields several classes of signaling modulators: activators, inhibitors, and attenuators of
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In vitro peptide selection methods have been widely successful in isolating ligands for
biological targets (14,15). Various proteins in the G protein signaling pathway have been
targeted by selection libraries, including receptors and Gα and Gβγ subunits (8). mRNA display
is a selection technique where each peptide in a library is covalently coupled with its encoding
mRNA (16,17). Previously, we used mRNA display selection to identify a peptide (R6A) and
its core motif (R6A-1) that bind with high affinity and specificity to the GDP-state of Gα
subunits (18,19). R6A and R6A-1 act as GDIs and compete with Gβγ for binding to Gαi1
(18,19). We hypothesized that the 9-residue R6A-1 sequence could be used as a scaffold for
developing new peptide ligands with different activities and/or specificities for Gα subunits.
Here we design an mRNA display library based on the R6A-1 core motif and use in vitro
selection to identify unique peptides that differentially modulate G protein signaling.
A DNA template was constructed to encode the R6A-1 peptide (DQLYWWEYL) flanked by
random hexamers on each end (see Methods). Nucleotide incorporation was controlled such
that each wild-type residue in the core motif was ~40–50% conserved (20). mRNA display
selection was performed on N-terminally biotinylated Gαi1 (Nb-Gαi1) due to the previous
finding that R6A-derived peptides bind preferentially to Nb-Gαi1 over the C-terminally
biotinylated Cb-Gαi1 (18). Aluminum fluoride (AlF) was supplemented into the selection
buffer to attempt to select for peptides specific for the GDP-AlF state of Gαi1, a transition state
mimic of GTP hydrolysis (21,22). AlF (either as AlF3 or AlF4−) has been shown to activate
Gα subunits—preventing association with Gβγ heterodimers—and GAPs have been shown to
bind exclusively to this transition state mimic. Six rounds of selection were performed and
significant binding was observed by the third round (Fig. 1a). Based on the starting library
complexity of ~2 × 1013 and a maximum enrichment of 10,000-fold per round, we estimate
that the third round input pool contained more than 100,000 unique, Gαi1-binding peptide
sequences. To enrich for peptides specific for the AlF-bound state of Gαi1, the fifth and sixth
round pools were pre-cleared against Gαi1-GDP prior to selection against Gαi1-GDP-AlF.
DNA sequencing of clones from the sixth round pool showed that the core 9-mer was primarily
conserved, except for a preference for Leu instead of Gln in the second position (Fig. 1b and
Table 1 in the Supporting Information). The random hexamer regions showed no obvious
sequence conservation, although the residues directly flanking the core motif favored several
amino acids including Leu, Asp, and Glu. In vitro binding assays with individual clones
revealed that the peptides bind ~1–40% to immobilized Gαi1-GDP-AlF (Fig. 1c). The wide
range of binding may suggest that the selection was not complete, or that specificity to the AlF-
bound state of Gαi1 produces a trade-off in overall binding.
Binding assays of individual peptides to Gαi1-GDP in the presence or absence of AlF show
that most peptides favor the GDP-bound state (Fig. 1c). Hence, the selection identified peptides
with a loss of specificity, compared with the original R6A sequence. Only one peptide, AR6-04,
exhibited better binding in the presence of AlF, but this peptide appears to have significantly
lower affinity for Gαi1 than other peptides. Because the selected peptides bind both states, pre-
clearing the fifth and sixth round pools on Gαi1-GDP may have removed the highest affinity
peptides while only marginally enriching for specificity to Gαi1-GDP-AlF.
AR6-04 and AR6-05 exhibited the highest AlF/GDP-state binding ratios for Gαi1 and were
synthesized for further characterization. Their affinities to immobilized Gαi1-GDP were
determined by surface plasmon resonance (SPR). Corresponding with the lower binding seen
in the in vitro assays, the KD of AR6-04 for Gαi1-GDP appears to be >10 µM. Conversely,
AR6-05, with an apparent KD of ~10 nM, is the highest affinity Gα-directed peptide that we
have tested, binding more than 6-fold better to Gαi1-GDP than our previously described R6A
peptide, and more than 20-fold better than the R6A-1 core motif (18). While R6A and R6A-1
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show clear 1:1 bimolecular binding kinetics, AR6-05 binding data were well fit only with a
more complex kinetics model (Fig. 1 in the Supporting Information).
R6A and R6A-1 were previously shown to compete with Gβγ heterodimers for binding to
Gαi1 in vitro (18,19). Binding of radiolabeled Gβ1γ2 to immobilized Gαi1 in the presence or
absence of peptides was performed to determine the peptide effects on Gβγ association. AR6-05
competes with Gβγ for binding to Gαi1 (Fig. 2a). Like the R6A peptide, binding of Gαi1 to
immobilized AR6-05 precludes Gβγ association (Fig. 2c).
Surprisingly, AR6-04 appears to enhance Gβ1γ2 binding to Gαi1. Several in vitro assays were
performed that support this observation: (1) labeled Gβγ shows higher binding to immobilized
Gαi1 in the presence of free AR6-04 peptide (Fig. 2b), (2) labeled AR6-04 peptide shows 66%
higher binding to immobilized Gαi1 in the presence of Gβ1γ2, and (3) experiments with labeled
Gαi1β1γ2 show that immobilized AR6-04 is able to pull down all three subunits (Fig. 2c).
To test the activity of the peptides in a cellular context, we used a HEK293 cell line expressing
the inwardly rectifying potassium channels, GIRK1 and 2, and the dopamine D2S GPCR.
Previous cell culture studies have shown that, similar to the G protein specificity observed in
vivo, only Gi/o-coupled receptors activate GIRK channels (23,24). In these cells, GIRK
channels are the dominant downstream effectors of released Gβγ subunits. The GPR consensus
peptide (10) was previously shown to attenuate signaling events after an initial agonist
application, without affecting basal GIRK activity (25). The authors hypothesized that the GPR
peptide is able to interact with Gα subunits only after an initial activation, which frees Gα for
peptide binding. We confirmed these results with the L19GPR peptide, which differs from the
GPR consensus at a redundant residue (10,18,26). In the absence of peptide, the kinetics of
channel deactivation (τ, deactivation time constant) are similar after short (τa) followed by long
(τb) dopamine applications (10.6 ± 1.9 s, n = 10 and 13.7 ± 3.4 s, n = 7, respectively, p = 0.68,
Fig. 3a). In contrast, L19GPR increased τb significantly compared with controls (Fig. 3b and
c). GIRK basal activity returned to its initial values after ~2 min from the dopamine washout,
indicating that the L19GPR peptide effect is transient, since a persistent effect should have
resulted in higher basal activity.
R6A exhibited similar effects to the L19GPR peptide. R6A increased τb moderately while the
negative control peptide C-GPR had no effect (Fig. 3d). R6A had minimal effect on the basal
GIRK channel activity (n = 7, p = 0.18) which suggests that, like the GPR peptide, R6A is
unable to dissociate Gαβγ heterotrimers in vivo. In contrast to R6A, intracellular application
of AR6-05 increased basal activity dramatically, suggesting that AR6-05 actively dissociates
Gβγ from Gα in vivo (Fig. 4).
AR6-04 had no effect on the deactivation kinetics (Fig. 3d), but instead directly reduced basal
GIRK activity (Fig. 4). This coincides with the in vitro binding data, where AR6-04 stabilizes
a heterotrimer complex and presumably reduces the active Gβγ available for GIRK channel
activation. It is not clear how AR6-04 stabilizes the heterotrimer despite being selected against
the Gα subunit alone. The peptide sequence differs greatly from the original R6A-1 core motif.
The flanking regions of AR6-04, however, share modest sequence similarity to the short
Gβγ-binding motifs previously identified (12), suggesting that other molecules that shut down
G protein signaling may be constructed by fusing known Gα- and Gβγ-specific ligands.
The R6A-1 based peptide library should be useful for the selection of peptides that are specific
for various G protein subclasses or nucleotide-bound states. Given the large number of Gαi1-
binding peptides identified here, unique functions, such as specificity for Gαi1 over other Gα
subunits, may have yet to be identified. While it is clear that AR6-04 and AR6-05 affect GIRK
channel activity—an effector of Gβγ—the peptide effects on Gα-regulated pathways and Gα
nucleotide-bound states have yet to be determined. For example, because GAPs have been
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shown to catalyze GTP hydrolysis by stabilizing a transition state (21,22), selected peptides
that bind Gαi1-GDP-AlF may act as small molecule GAPs. Although further technological
advances are necessary for the facile conversion of peptides to therapeutics, determining the
mechanism of action of the AR6-04 and AR6-05 peptides will facilitate the rational design of
more potent modulators of G protein signaling for use as biological tools and potential drug
leads.
Methods
Materials
Human cDNA clones for G proteins were obtained from the UMR cDNA Resource Center
(http://www.cdna.org) in the pcDNA3.1+ vector (Invitrogen). The Gγ2 cDNA vector encoded
an N-terminal HA tag. Anti-HA mAb (clone HA-7) was obtained from Sigma. Expression
of 35S-Met–labeled G proteins by in vitro translation was performed as described previously
(19).
mRNA display selection
The doped R6A-1 library was constructed by PCR amplification of oligo 115.1 [5’-AGC AGA
CAG ACT AGT GTA ACC GCC (SNN)6 (S13) (641) (542) (521) (521) (641) (S13) (543)
(642) (SNN)6 CAT TGT AAT TGT AAA TAG TAA TTG TCC C; 1 = 7:1:1:1, 2 = 1:7:1:1,
3 = 1:1:7:1, 4 = 1:1:1:7, A:C:G:T; 5 = 9:1, 6 = 1:9, C:G; N= A, C, G, OR T; S = C OR G (ratios
have been adjusted for synthesis incorporation rates)] with primers 47T7FP (5’-GGA TTC
TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT AC) and 22.9 (5’-
AGC AGA CAG ACT AGT GTA ACC G) to produce dsDNA encoding M-X6-
DQLYWWEYL-X6-GGYTSLSA, with the core 9-residues conserved ~40–50%. Sequencing
of randomly chosen clones from the initial pool revealed a distribution of wild-type residues
in the core motif that agreed with theoretical calculations (data not shown). In vitro
transcription, ligation of the mRNA to the puromycin linker, and purification of the RNA-F30P
template were performed as described previously, except that the splint oligo 23.8 (5’-TTT
TTT TTT TTN AGC AGA CAG AC) was used for the ligation reaction (18). RNA-peptide
fusions were prepared, purified on oligo-dT cellulose, reverse-transcribed with oligo 22.9, and
selected against immobilized N-terminally biotinylated Gαi1 (Nb-Gαi1) as described
previously using a modified selection buffer [25 mM HEPES-KOH at pH 7.5, 150 mM NaCl,
0.05% (v/v) Tween 20, 1 mM β-mercaptoethanol, 10 µM GDP, 20 µM EDTA, 5 mM
MgCl2, 10 mM NaF, 25 µM AlCl3, 0.05% (w/v) BSA, and 1 mg mL−1 yeast tRNA] (18).
RNA-peptide fusion binding assay
Purified, RNase-treated mRNA display peptide fusions of individual clones were assayed for
binding as described previously (27). Briefly, aliquots of 35S-labeled fusions were added to
~15 µL of Nb-Gαi1 (~15 µg protein) on streptavidin agarose (immobilized NeutrAvidin on
agarose, Pierce) in 1 mL of selection buffer. After binding for 1 h, the matrices were washed
with 3 × 0.6 mL of selection buffer in a 0.45 µm cellulose acetate spin filter (CoStar Spin-X,
Corning). Input 35S counts for binding assays were determined by scintillation counting of the
washes and the matrix. Bound 35S counts were divided by the input counts to calculate the
fraction bound. Binding of RNase-treated peptide fusions to the immobilization matrix alone
was less than 0.001. Assays for binding to Gαi1-GDP were performed in selection buffer
without AlF.
in vitro peptide studies
Peptides were synthesized with the first 3 residues of the C-terminal constant tag (GGY) and
purified by Bio-Synthesis, Inc. Three additional C-terminal lysines were added to the AR6-04
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peptide to enhance solubility. SPR affinity measurements were made on immobilized Nb-
Gαi1 as described previously (18). Peptide effects on Gβγ association with immobilized Nb-
Gαi1 were assayed by mixing an aliquot of 35S-labeled Gβ1γ2 with ~15 µL of immobilized Nb-
Gαi1 in 1 mL of selection buffer without AlF. After rotating at 4 °C for 1 h, samples were
washed with 3 × 0.6 mL of the binding buffer in a spin filter, as described above. Binding was
determined by scintillation counting and scaled to the amount of Gβγ pulled down in the
absence of peptide. Data are background subtracted from binding to matrix without
immobilized Gαi1 (~10% of overall binding). AlF reduced Gβ1γ2 pull down on Nb-Gαi1 to
~50%.
Gαβγ heterotrimer immunoprecipitation
AR6-04 and AR6-05 were expressed as MBP fusion proteins and immobilized by random
amine coupling on CNBr-Sepharose 4B (GE Healthcare) as described previously (19). 35S-
labeled Gαβγ heterotrimer was immunoprecipitated with anti-HA monoclonal antibody and
protein G-sepharose, or pulled down on immobilized MBP as described previously (19).
Recovered proteins were separated by SDS-PAGE. Gels were imaged by autoradiography
(Storm PhosphorImager, GE Healthcare).
Electrophysiology
We used HEK293 cell lines stably expressing GIRK1, GIRK2a, and the Gi/o-coupled dopamine
(D2s) receptor (23). The pipette solution contained 107 mM KCl, 1.2 mM MgCl2, 1 mM
CaCl2, 10 mM EGTA, 5 mM HEPES at pH 7.4, 2 mM MgATP, and 0.3 mM Na2GTP. Peptides
were added to the pipette solution immediately prior to recording. The final DMSO
concentration was 0.5% (v/v) or less. The bath solution contained 2.6 mM CaCl2, 1.2 mM
MgCl2, 5 mM HEPES at pH 7.4, and either 140 mM KCl (High-K+) or 140 mM NaCl (Zero-
K+). Membrane currents were recorded in a whole-cell patch-clamp mode with an Axopatch
200B amplifier (Axon Instruments), and a patch pipette resistance of 2.5–4.5 MΩ. Data were
filtered at 1 kHz and digitized at 5 kHz. Cell capacitance was 12–18 pF, and series resistance
(5– 20 MΩ) was at least 75% compensated on-line. Current recording was acquired after
equilibration for ~5 min in gap-free mode at −80 mV. Dopamine (2 µM, Sigma) was applied
in bath solution via an N2-pressurized perfusion system (ALA Scientific Instruments).
Data analysis
Data acquisition and analysis was done by a Digidata 1200A interface (Axon Instruments) and
pClamp 8.2 and Microcal Origin 6.0 software. The deactivation time constants (τ) were
determined in pClamp (standard exponential). Currents were averaged over 17 ms to reduce
60 Hz background noise. All data are presented as mean ± s.e.m.. Statistical significance was
determined by non-paired, two-tailed student’s t tests. In figures: *, p < 0.05; **, p < 0.01; ***,
p < 0.0001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
In vitro selection targeting Gαi1-GDP-AlF. (a) Fraction of 35S-Met–labeled mRNA display
pools from each round of selection bound to immobilized Gαi1-GDP-AlF and recovered by
elution with SDS. The inputs for the fifth and sixth rounds were pre-cleared against Gαi1-GDP
prior to selection. (b) Sequences of peptides used in in vitro studies. The region corresponding
to the R6A-1 core motif is boxed (grey). The C-terminal constant region is not shown. (c)
Binding of individual, RNase-treated, 35S-Met–labeled mRNA display fusions to Gαi1-GDP
or Gαi1-GDP-AlF. Except for AR6-04, all tested peptides have a preference for binding to
Gαi1-GDP.
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Figure 2.
AR6-04 and AR6-05 Gαi1-binding peptides differentially affect Gβγ association. (a) and (b)
Binding of 35S-Met–labeled Gβ1γ2 to immobilized Gαi1 in the presence or absence of AR6-05
(20 µM) or AR6-04 (33 µM). AR6-05 competes with Gβγ for association to Gαi1 (n = 4, p =
0.0050) while AR6-04 increases Gβγ binding (n = 3, p = 0.041). DMSO (~1%, vol/vol) had
no effect on Gβγ binding (n = 3, p = 0.50). (c) Binding of 35S-Met–labeled Gαi1β1γ2 to
immobilized peptides. Anti-hemagglutinin (HA) antibody immunoprecipitates the HA-tagged
Gγ2 subunit and confirms the presence of reconstituted heterotrimers. Immobilized maltose-
binding protein (MBP) fails to pull down G proteins while binding of Gαi1 to immobilized
AR6-05–MBP completely precludes Gβ1γ2 association. AR6-04–MBP, however, pulls down
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the intact heterotrimer. The control MBP lane is shown again at the same contrast as the AR6-04
lane for comparison.
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Figure 3.
Effect of intracellular application of peptides on GIRK deactivation kinetics. (a) HEK293 cells
stably expressing GIRK1 and 2 and the dopamine receptor D2s were recorded by whole-cell
patch-clamp (see Methods). Zero-K+ buffer (red bar) was perfused for 4 sec to determine GIRK
basal activity. Application of dopamine for 4 and 30 sec (green bars) activated GIRK currents.
Dopamine washout was followed by GIRK channel deactivation. τa and τb are the GIRK
deactivation time constants following the short and long dopamine applications, respectively.
The dotted line represents 0 pA. (b) Superposition of representative current traces of cells
recorded in the presence of 2 µM of the control peptide L19GPR-R23L (black) or the L19GPR
peptide (red). L19GPR-R23L is a negative control peptide which contains a mutation to a
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critical Arg residue (26). Current traces were normalized to cell membrane capacitance and
current amplitude in Zero-K+ buffer was subtracted from current traces in High-K+ buffer.
(c) L19GPR (2 µM) increases τb after prolonged dopamine application (n = 7, p = 3.9 ×
10−5) while the control L19GPR-R23L peptide (2 µM) has no effect (n = 2, p = 0.71). %
Δτdeact is the percentage change of τb from τa. (d) R6A (100 µM) moderately increases τb (n
= 4, p = 0.0065) while AR6-04 (40 µM, n = 5, p = 0.49) and the control C-GPR peptide (100
µM, n = 5, p = 0.44) have no effect. AR6-05 (40 µM) appears to increase τb (n = 5, p = 0.13)
but there is significantly increased error in the kinetics measurements likely due to the effect
that AR6-05 has on basal GIRK activity. In (c) and (d), the control contains <0.5% (v/v) DMSO.
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Figure 4.
Intracellular application of 40 µM AR6-05 or AR6-04 increases (n = 4, p = 0.0046) or decreases
(n = 5, p = 0.027) basal GIRK currents, respectively. Current densities are determined by
normalization with the individual cell capacitance. The control contains <0.5% (v/v) DMSO.
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